Cancer Research · 2004 · 68 citations · 29 references
Life SciencesMedicinal ChemistryPharmacologyCell SignalingDrug DiscoverySignal TransductionAngiogenesisAngiogenesis In CancerGrowth Factor SignalingReceptor Tyrosine Kinase SignalingMitogen-activated Protein Kinase CascadesMitogen-activated Protein Kinase PathwaysPlatelet-derived Growth Factor InhibitionPlatelet-derived Growth Factor ReceptorsTumor Angiogenesis SignalingVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptor SignalingVascular Endothelial Growth Factor Signaling
A small synthetic library of cyclohexapeptidomimetic calixarenes was prepared to identify disrupters of vascular endothelial growth factor (VEGF) binding to its receptor that inhibits angiogenesis. From this library, we discovered GFA-116, which potently inhibits (125)I-VEGF binding to Flk-1 in Flk-1-overexpressing NIH 3T3 cells and human prostate tumor cells with an IC(50) of 750 nM. This inhibition is highly selective for VEGF in that (125)I- platelet-derived growth factor binding to its receptor is not affected. GFA-116 inhibits VEGF-stimulated Flk-1 tyrosine phosphorylation and subsequent activation of Erk1/2 mitogen-activated protein kinases. Furthermore, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor-dependent stimulation of Erk1/2 phosphorylation are not affected at concentrations as high as 10 microM. In vitro, GFA-116 inhibits angiogenesis as measured by inhibition of migration and formation of capillary-like structures by human endothelial cells as well as suppression of microvessel outgrowth in rat aortic rings and rat cornea angiogenesis. In vivo, GFA-116 (50 mpk/day) inhibits tumor growth and angiogenesis as measured by CD31 staining of A-549 human lung tumors in nude mice. Furthermore, GFA-116 is also effective at inhibiting tumor growth and metastasis to the lung of B16-F10 melanoma cells injected into immunocompetent mice. Taken together, these results demonstrate that a synthetic molecule capable of disrupting the binding of VEGF to its receptor selectively inhibits VEGF-dependent signaling and suppresses angiogenesis and tumorigenesis.
29
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Peter Carmeliet, Valérie Ferreira, Georg Breier et al. · Nature · 1996 · 4.1K citations
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Fouad Shalaby, Janet Rossant, Terry P. Yamaguchi et al. · Nature · 1995 · 3.9K citations
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Napoleone Ferrara, Karen Carver-Moore, Helen Chen et al. · Nature · 1996 · 3.7K citations · Full text
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Jocelyn Holash, Peter C. Maisonpierre, Debra Compton et al. · Science · 1999 · 2.2K citations
Medicine, Cancer Biology, Oncology +17